

GOVERNMENT OF NATIONAL CAPITAL TERRITORY OF DELHI
DEPARTMENT OF HEALTH & FAMILY WELFARE
9th LEVEL, 'A' WING, DELHI SECRETARIAT, NEW DELHI-110002

F.No. 600/DGHS/PHW-IV/COVID-19/Mucormycosis/2021/Prsecyhfwo/5644-5719 Dated: 26/05/2021

ORDER

Mucormycosis is being detected among patients who are recovering or have recovered from COVID-19. A reporting format has been designed, and hosted on the COVID portal: (www.covid19.nhp.gov.in) that can be accessed & filled up by the IDSP District Surveillance Officers (DSOs). The timely data upload is crucial to ensure allocation of Liposomal Amphotericin B by MoHFW, GoI to NCT of Delhi.

All Govt. & Pvt. medical facilities in NCT of Delhi are directed to report of Mucormycosis case data as per enclosed format to their concerned District Surveillance Officers (DSOs) on a daily basis by 4:00pm, on their concerned mail IDs as mentioned.

Enclosures:


1. D.O. dated: 21.05.2021 from Director, NCDC
2. D.O. dated: 24.05.2021 from Secretary, H&FW, MoHFW
3. List of District-Wise Mail IDs for Daily Data Sharing
4. Reporting Format for Mucormycosis case data


26/5/21
(Vikram Dev Dutt)
Pr. Secretary (H&FW)

F.No. 600/DGHS/PHW-IV/COVID-19/Mucormycosis/2021/Prsecyhfwo/5644-5719 Dated: 26/05/2021

Copy to:

1. ACS (Power)/Nodal Officer-COVID-19, GNCT of Delhi.
2. OSD to Hon'ble MOH, GNCTD.
3. All Secretaries (Health & FW), GNCT of Delhi.
4. All Spl. Secretaries (H&FW)/ All OSDs (H&FW).
5. Director General of Health Services, GNCTD.
6. Director, Dte. Of Family Welfare, GNCTD
7. MSs/MDs of all hospitals (Delhi Govt., Central Govt., Railway, Army, Autonomous, Hospitals under local bodies).
8. All DMs, GNCTD.
9. CDMOs (All Districts, GNCTD).
10. DSOs (All Districts, GNCTD).
11. MD/MS/Caretaker of all Private hospitals through MS(NH), DGHS, GNCTD.
12. Guard File.


26/5/21
(Vikram Dev Dutt)
Pr. Secretary (H&FW)



समृद्धि जगते

मानव कल्याण

राष्ट्रीय रोग नियंत्रण केन्द्र
(जनसंख्या रोग नियंत्रण केन्द्र)
इलाहाबाद एवं पंडितार नगर नगर, उत्तर प्रदेश
22, शम नरथ मार्ग, दिल्ली - 110064

Government of India

NATIONAL CENTRE FOR DISEASE CONTROL

(Formerly Known as National Institute of Communicable Diseases (NICD))

Directorate General of Health Services
Ministry of Health & Family Welfare, Government of India
22, Shom Nath Marg, Delhi-110064



देश: भारत
राज्य: उत्तर प्रदेश
जिला: इलाहाबाद
पता: इलाहाबाद नगर नगर, उत्तर प्रदेश
22, शम नरथ मार्ग, दिल्ली - 110064

Dr. Sujeet K Singh
MD, DCH
Director

DO No. T.18015/051/2021-105P
Dated: 21st May 2021

Subject: Regular reporting of Mucormycosis cases (as a notifiable disease)- reg.

Dear All

This pertains to media reports wherein an increase in no. of cases of Mucormycosis has been reported from some States in the recent times. Further, to this, States have been requested to declare Mucormycosis as notifiable disease. In order to get authentic figures and a clear picture of the associated factors, a reporting format has been designed and hosted on the covid portal: www.covid19.nhp.gov.in that can be accessed & filled up by the IDSP district surveillance officers (DSOs). The DSOs are advised to coordinate with the District Magistrates in their respective districts to get data from hospitals in this regard. A guidance document with SOPs in this regard is enclosed.

You are requested to share the SOPs with the concerned district level officials and initiate reporting at the earliest. Your State may contact Dr Himanshu Chauhan, Joint Director, NCDC at himanshu.chauhan@nic.in in case of any further information / assistance required.

With regards,

Yours Sincerely,


(Sujeet Kr. Singh)

Encl.: As above.

To:
IDSP State Surveillance Officer of all States/UTs



Antibiotic Resistance Containment Stewardship: Our Role, Our Responsibility
Judicious Use of Antibiotics: Key to Contain Antibiotic Resistance



SOPs for reporting Mucormycosis from District/State

1. Mucormycosis is a fungal infection that mainly affects people who are on medication for other health problems that reduces their ability to fight environmental pathogens. Currently, Country is witnessing an apparent rise in number of Mucormycosis cases among patients hospitalised for management of COVID-19. These cases has also been observed to have worse clinical outcomes & high mortality.
2. In this context, there is a need to have a standard reporting system for Mucormycosis cases observed among confirmed COVID-19 as well as non-confirmed COVID-19 cases from Government and Private facilities managing such cases. Due to its spread & high mortality, such cases are majorly being reported from tertiary care hospitals.
3. Provision of daily reporting of Mucormycosis cases has been made in covid portal. District Surveillance Officer will be overall responsible of reporting Mucormycosis cases in S3 portal being managed in tertiary level Government & Private health care facilities in his/her district.
4. The daily flow of information from tertiary level Government & Private health care facilities to District Health Department (DSO) and its subsequent entering in S3 portal by DSO will be facilitated by District Magistrate/ Collector. It is extremely crucial to have smooth flow of desired information from Medical institutions to Health Department.
5. Regular sensitization meetings under the Chairmanship of DM/DC may be conducted to streamline the flow of information.

Flowchart for reporting Mucormycosis cases

Daily sharing of Mucormycosis reports (formal) from tertiary level Government & Private health care facility to DM/DC Office by 01.00 PM

Sharing of Daily report with DSO by DM/DC Office

Daily entering of reports in Mucormycosis S3 portal by DSO



भारत सरकार
स्वास्थ्य एवं परिवार कल्याण विभाग
स्वास्थ्य एवं परिवार कल्याण मंत्रालय
Government of India
Department of Health and Family Welfare
Ministry of Health and Family Welfare

राजेश भूषण, आईएएस
सचिव

RAJESH BHUSHAN, IAS
SECRETARY

D.O. No.A-45013/26/2021-HPE
24th May 2021

Dear Chief Secretary,

This takes reference of DO letter Number T-18015/051/2021-IDSP dated 19th May, 2021 from the Ministry wherein all the States/UTs had been requested to make Mucormycosis a Notifiable disease under Epidemic Disease Act, 1897. (copy enclosed). This was followed by letter dated 21.05.2021 by Director, NCDC advising the States Surveillance Officer to upload the Covid portal (www.covid19.nhp.gov.in) with the required data concerning Mucormycosis cases.

2. It has been noted that only 18 States, till the morning of 24.05.2021, have uploaded the portal with the required information. Even the information about the number of cases provided by the States is at variance with what had been informed earlier by them to the Department of Pharmaceuticals (DoP) / Ministry of Health & Family Welfare (MoHFW) through various channels.

3. DoP has been making allocations of the drug Liposomal Amphotericin B to the States/UTs/Central institutions based on the above information. However, any future allocations shall be based only on the data provided on the Central Covid-19 portal by the States/UTs.

4. It is, therefore, requested that the requisite updated information about Mucormycosis cases may be got uploaded on the above referred Central portal for Covid-19 at the earliest.

Regards.

Yours sincerely,

(Rajesh Bhushan)

Encl : as above

Chief Secretary / Administrator
All States/UTs.

Rajesh Bhushan
25/05/2021

Dr. Anshu



भारत सरकार
स्वास्थ्य एवं परिवार कल्याण विभाग
निर्माण भवन, नई दिल्ली - 110011

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
NIRMAN BHAVAN, NEW DELHI - 110011

LAV AGARWAL, IAS

Joint Secretary

TEL : 011-23061186
T/Fax : 011-23061842
E-mail : lav@nhm.nic.in

DO Letter No: T 18015/051/2021-IDSP
Dated on: 19th May, 2021

Dear Sir/Madam,

I sincerely appreciate the efforts put in by your State to manage this pandemic of COVID 19 and tackling new challenges being thrown by this disease. In recent times a new challenge in the form of a fungal infection namely MUCORMYCOSIS has emerged and is reported from many States amongst COVID 19 patients especially those on steroid therapy and deranged sugar control. This fungal infection is leading to prolonged morbidity and mortality amongst COVID 19 patients.

The treatment of this fungal infection requires multidisciplinary approach consisting of Eye surgeons, ENT specialists, General Surgeon, Neurosurgeon and Dental Maxillo facial surgeon etc and institution of Amphotericin B as an antifungal medicine.

You are requested to make mucormycosis a notifiable disease under Epidemic Diseases Act 1897, wherein all Government and Private health facilities, Medical Colleges will follow guidelines for screening, diagnosis, management of mucormycosis, issued by MoHFW (GoI) and ICMR and make it mandatory for all these facilities to report all suspected and confirmed cases to Health Department through district level Chief Medical Officer and subsequently to IDSP surveillance system.

We look forward for your support in this.

With regards,

Yours sincerely


(Lav Agarwal)

ACS / Principal Secretary (Health) / Principal Secretary (Medical Education) / MD NHMs -
All States and UTs

List of District Wise Mail IDs created for Daily Mucormycosis data reporting by concerned Govt. & Pvt. Health Facilities (As per data format)

Sr.No.	District	Email ID
1	East	mucoreast@gmail.com
2	West	mucorwest@gmail.com
3	North	mucornorth@gmail.com
4	South	mucorsouth@gmail.com
5	North East	mucornortheast@gmail.com
6	North West	mucornorthwest@gmail.com
7	South East	mucorsoutheast@gmail.com
8	South West	mucorsouthwest@gmail.com
9	Central	mucorcentral@gmail.com
10	Shahdara	mucorshahdara@gmail.com
11	New Delhi	mucornewdelhi@gmail.com

Case Reporting State	Case Reporting District	Name of the Hospital where admitted/ diagnosed	Name of Hospital Nodal Officer	Mobile Number of the contact person	Name of Patient	Father's Name	Age	Gender	Attendant Name	Contact Number (Patient/ Attendant)	House No. & Street/ Locality Name	Village	State	District	Pincode
								Male							
								Female							
								Others							

Whether patient have COVID History	Date of RAT or RT-PCR testing	Please provide ICMR ID/SRF ID, if available	Date on which Mucormycosis diagnosed	Classification of Mucormycosis	Patient Medical Status	Diabetes	Immuno compromised Status	Other comorbidity, if any	Whether received steroid therapy during treatment	whether oxygen support received prior to onset of mucormycosis	Remarks, if any
				cutaneous	cured	Yes	Yes	cancer chronic	yes	yes	
				disseminated	death	No	No	chronic lung disease	no	no	
				gastrointestinal	under treatment			heart disease			
				pulmonary				hypertension			
				rhinocerebral				kidney disease			
				uncommon presentations				over weight/obesity			

* Column Heads highlighted are Mandatory Fields for reporting



- Dashboard
- Reports
- Positive Cases Mgmt
- Hospital Analysis
- ICMR ID/ SRF ID
- Accredia Sfty
- COVID-19 App
- Surveys
- Case and Infa Analysis
- Surveillance
- Resources

VIEW RECORDS

Mucormycosis cases- Patient data entry form

Hospital Information :

* Case Reporting State	Delhi
* Case Reporting District	SOUTH
* Name of the Hospital where admitted/diagnosed	
Name of hospital nodal officer	
Mobile number of the contact person	

Patient Information :

* Name of Patient	
* Father's Name	
* Age	
* Gender	Select Gender
Attendant Name	
Contact number (Patient/Attendant)	

Patient Address :

* House No. & Street/locality name	
Village	
* State	Select State
* District	Select District
Pincode	

Medical Details :

* Whether patient have COVID History?	<input checked="" type="radio"/> Yes <input type="radio"/> No
Date of RAT or RT-PCR testing	dd-mm-yyyy
Please provide ICMR ID/SRF ID, if available	
* Date on which Mucormycosis diagnosed	dd-mm-yyyy

- Dashboard
- Reports
- Positive Cases Month
- Heat Map Analysis
- Area Charts
- Area Graphs
- Case Facility App
- Analytics
- Case and Infig Analysis
- Surveillance
- Feedback

* Classification of Mucormycosis

Select Classification

* Patient Medical status

Select Present status

* Diabetes

Yes No

* Immunocompromised Status

Yes No

Other Comorbidity, if any

Cancer Chronic Chronic Lung disease

Heart disease Hypertension

Kidney Disease Over weight/ Obesity

Any other:

* Whether received steroid therapy during treatment

Yes No

* Whether oxygen support received prior to onset of mucormycosis

Yes No

Remarks, if any

SUBMIT